Ordering Recommendation
Aids in differentiation of inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) and other functional disorders of the gastrointestinal (GI) system. Aids in monitoring IBD and prediction of relapse.
Mnemonic
Methodology
Quantitative Chemiluminescent Immunoassay
Performed
Sun-Sat
Reported
1-3 days
New York DOH Approval Status
Specimen Required
Stool.
Transfer 5 g stool to an unpreserved stool transport vial (ARUP Supply #40910). Available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. (Min: 1 g)
Refrigerated.
Specimens in media or preservatives.
Ambient: Unacceptable; Refrigerated: 7 days; Frozen: 30 days
Reference Interval
49 µg/g or less | Normal |
50-120 µg/g | Borderline elevated, test should be re-evaluated in 4-6 weeks. |
121 µg/g | Elevated |
Interpretive Data
Fecal Calprotectin is an indicator of the presence of neutrophils in stool and is not specific for IBD. Other intestinal ailments including GI infections and colorectal cancer can result in elevated concentrations of calprotectin. The diagnosis of IBD cannot be established solely on the basis of a positive calprotectin result. Patients with IBD fluctuate between active and inactive stages of disease. Calprotectin results may also fluctuate.
FDA
Note
Hotline History
CPT Codes
83993
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
3002862 | Calprotectin, Fecal | 38445-3 |
Aliases
- Cal pro
- Calpro
- Fecal Calprotectin
- IBD
- IBS
- Stool Calprotectin